Challenging Denials of Experimental or Investigational Treatments

Innovative therapies are often labeled “experimental” or “investigational,” which can stall care even when evidence and biology point your way. We distinguish late-phase trials, real-world evidence–supported off-label use, and expanded access, then align the right pathway to your diagnosis and biomarkers. Our team builds a payer-ready case that cites compendia ratings, guideline footnotes, prior treatment failures, and documented intolerance to standard options. We prepare a safety and monitoring plan—drug–drug checks, lab cadence, imaging intervals, and toxicity thresholds—so reviewers see medical necessity and risk controls together. Consent materials are translated into plain English, with decision aids that compare benefits, uncertainties, and practical trade-offs. When trials fit, we vet inclusion/exclusion quickly, share records in the site’s format, and target locations with realistic enrollment windows. For expanded access, we coordinate clinician letters, manufacturer requests, IRB requirements, and any FDA submissions while mapping logistics and timelines. Cost responsibilities are clarified early—what insurance covers, what sponsors fund—and we pursue grants, travel support, or copay assistance as needed. Re-authorization triggers are planned upfront using measurable response criteria, so coverage can continue if you’re benefiting. Throughout, you keep clinical control: clear updates, a defined exit plan if results fall short, and seamless handoffs back to standard care when appropriate.